Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

by rvvadmin | Jun 10, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

by rvvadmin | Apr 23, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

by rvvadmin | Apr 18, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

by rvvadmin | Apr 2, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

by rvvadmin | Mar 27, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

by rvvadmin | Mar 19, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...